56926-42-2

Upstream product

• 124-38-9 carbon dioxide 
• 831-82-3 4-Phenoxyphenol 
• 109-72-8 n-butyllithium 
• 54582-60-4 2-bromo-4-phenoxy-phenol 
• 100-67-4 potassium phenolate 
• 859793-71-8 2-methoxy-5-phenoxy-toluene 
• 14804-31-0 2-methyl-4-bromoanisole 
• 63987-24-6 2-methoxy-5-phenoxy-benzoic acid 

Downstream Products

• 56926-43-3 Ethyl-5-phenoxysalicylat 
• 56926-34-2 2-acetoxy-4-phenoxyphenol 
• 56926-49-9 2-Benzyloxy-5-phenoxy-acetophenon 
• 56926-47-7 2-Benzyloxy-5-phenoxybenzoesaeure 
• 56926-45-5 Ethyl-2-benzyloxy-5-phenoxybenzoat 
• 56926-36-4 Ethyl-2,4-dioxo-4-(2'-hydroxy-5'-phenoxyphenyl)-butyrat 
• 136100-76-0 2-hydroxy-5-phenoxybenzoic acid methyl ester 

Relevant academic research and scientific papers

CHOLESTEROL ESTER HYDROLASE INHIBITORS

The compounds of the formula: in which R1 is alkyl of 4 or more carbon atoms, cycloalkyl, 1-adamantyl, 2-adamantyl, 3-noradamantyl, 3-methyl-1-adamantyl, 1-fluorenyl, 9-fluorenyl, cycloalkylalkyl, phenyl, substituted phenyl, alkyl, alkoxy, halo, nitro, cyano or trifluoromethyl, phenylalkyl or substituted phenylalkyl, where the substituent on the benzene ring is alkyl, alkoxy, halo, nitro, cyano, trifluoromethyl or phenyl; R2 is hydrogen, alkyl or R1 taken with R2 and the nitrogen atom to which they are attached form a heterocyclic moiety of the formula: wherein in which R7 is hydrogen, alkyl, hydroxy, alkanoyloxy, hydroxyalkyl, hydroxycarbonyl, alkoxycarbonyl, phenyl or substituted phenyl, in which the substituent is alkyl, alkoxy, halo, nitro, cyano, haloalkyl, perhaloalkyl or dialkylaminoalkyl; R8 is hydrogen or alkyl or R7 and R8 taken together are polymethylene; R9 is hydrogen, alkyl, phenyl or substituted phenyl, in which the substituent is alkyl, alkoxy, halo, nitro, cyano or perhaloalkyl; R10 is hydrogen, alkyl or gemdialkyl; n is one of the integers 0, 1 or 2; and R3, R4, R5 and R6 are, independently, hydrogen, alkyl, alkoxy, halo, nitro, cyano or perhaloalkyl, alkoxycarbonyl or hydroxycarbonyl; and when X is --NR9-- or R7 is an amino alkyl group, a pharmaceutically acceptable salt thereof; useful as inhibitors of cholesterol ester hydrolase

Synthesis of ethyl 6-substituted-chroman- and -chromone-2-carboxylates. A comparative structure-activity study employing the 6-phenyl and phenoxy analogs in the triton hyperlipidemic rat model.

To explore the effect of lipophilicity on antilipidemic activity in the Triton WR-1339 induced hyperlipidemic rat model we synthesized the 6-cyclohexyl, phenyl, and phenoxy analogs of ethyl chroman-2-carboxylate. Results obtained were analyzed in light of the biological activity observed for the 6-chloro-substituted and unsubstituted chromans, the 6-chlorochroman-4-one ester, and the 6-chloro-, phenyl-, and phenoxychromone esters. The suggestion is made that chromones likely exert their antilipidemic effects by a somewhat different set of mechanisms than do the chromans and clofibrate. Whereas the 6-chlorochromanone ester is inactive, the 6-chlorochromone ester is active in both normal and hyperlipidemic Sprague-Dawley rats. The major differential effect was observed for ethyl 6-cyclohexylchroman-2-carboxylate which did not lower cholesterol levels but returned triglyceride levels to normal in hyperlipidemic rats.